Andrew Fromkin
Director/Board Member chez IMMUNOVANT, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Andrew J.
Fromkin currently works at Proteovant Sciences, Inc., as Chief Executive Officer from 2021, Immunovant Sciences Ltd., as Director from 2019, Immunovant, Inc., as Director from 2019, and Roivant Sciences, Inc., as Partner-Vant Portfolio from 2021.
Mr. Fromkin also formerly worked at Clinical Data, Inc., as Chief Executive Officer in 2011, Radius Health, Inc., as President, Chief Executive Officer & Director in 2013, DoctorQuality, Inc., as President & Chief Executive Officer from 2000 to 2004, Endo Surgical Devices, Inc., as President, Chief Executive Officer & Director, Tarveda Therapeutics, Inc., as Chairman & Chief Executive Officer from 2020 to 2021, Regado Biosciences, Inc., as Director from 2014 to 2016, Avalon Pharmaceuticals, Inc., as Director in 2009, Tobira Therapeutics, Inc., as Independent Director from 2015 to 2016, Immunovant, Inc., as Director, Health Information Technology, as Director-Marketing & Payer Alliance, and Merck-Medco Managed Care LLC, as Vice President-Business Development from 1993 to 2000.
Mr. Fromkin received his undergraduate degree from Brandeis University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNOVANT INC
0,07% | 02/04/2024 | 99 913 ( 0,07% ) | 3 M $ | 31/03/2024 |
Postes actifs de Andrew Fromkin
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOVANT, INC. | Director/Board Member | 18/12/2019 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2021 |
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Director/Board Member | 01/10/2019 |
Proteovant Sciences, Inc.
 Proteovant Sciences, Inc. BiotechnologyHealth Technology Part of SK, Inc., Proteovant Sciences, Inc. develops a bi-functional molecular technology platform. The private company is based in White Plains, NY. The company was founded in 2020. Andrew J. Fromkin has been the CEO of the company since 2021. Proteovant Sciences was acquired by SK Biopharmaceuticals Co., Ltd. from Roivant Sciences Ltd. on August 12, 2023 for $61,954.25 million. | Chief Executive Officer | 01/01/2021 |
Anciens postes connus de Andrew Fromkin
| Sociétés | Poste | Fin |
|---|---|---|
Tarveda Therapeutics, Inc.
 Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA. | Chief Executive Officer | 30/09/2020 |
| TOBIRA THERAPEUTICS INC | Director/Board Member | 31/10/2016 |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Director/Board Member | 01/01/2016 |
| RADIUS HEALTH, INC. | Chief Executive Officer | 26/11/2013 |
Clinical Data, Inc.
 Clinical Data, Inc. Medical SpecialtiesHealth Technology Clinical Data, Inc. manufactured and distributed scientific instruments used in clinical and analytical laboratories. The company was founded in 1972 and was headquartered in Newton, MA. | Chief Executive Officer | 01/05/2011 |
Formation de Andrew Fromkin
| Brandeis University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMUNOVANT, INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
Clinical Data, Inc.
Clinical Data, Inc. Medical SpecialtiesHealth Technology Clinical Data, Inc. manufactured and distributed scientific instruments used in clinical and analytical laboratories. The company was founded in 1972 and was headquartered in Newton, MA. | Health Technology |
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Merck-Medco Managed Care LLC
 Merck-Medco Managed Care LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck-Medco Managed Care LLC discovers, develops, and markets a broad range of human and animal health products. The private company is based in Whitehouse Station, NJ. | Health Technology |
Avalon Pharmaceuticals, Inc.
 Avalon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD. | Health Technology |
DoctorQuality, Inc.
 DoctorQuality, Inc. Medical DistributorsDistribution Services DoctorQuality, Inc. provides medical equipment. The American company was founded by David J. Shulkin. | Distribution Services |
| Endo Surgical Devices, Inc. | |
Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA. | Health Technology |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Immunovant, Inc. /Old/
 Immunovant, Inc. /Old/ BiotechnologyHealth Technology Immunovant, Inc. is a biopharmaceutical company, which engages in the development of therapies for autoimmune diseases. It focuses on its product pipeline, IMVT-1401, which is a human recombinant anti-neonatal Fc receptor monoclonal antibody for the treatment of IgG mediated diseases. The company is headquartered in New York, NY. | Health Technology |
Immunovant Sciences Ltd.
Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Health Technology |
| Health Information Technology | Government |
Proteovant Sciences, Inc.
Proteovant Sciences, Inc. BiotechnologyHealth Technology Part of SK, Inc., Proteovant Sciences, Inc. develops a bi-functional molecular technology platform. The private company is based in White Plains, NY. The company was founded in 2020. Andrew J. Fromkin has been the CEO of the company since 2021. Proteovant Sciences was acquired by SK Biopharmaceuticals Co., Ltd. from Roivant Sciences Ltd. on August 12, 2023 for $61,954.25 million. | Health Technology |
